Contact St. Luke’s Cancer Research Program Office at 832-355-3490 if you have questions.

Breast Cancer Prevention

SLEH 2006 Study of Tamoxifen and Raloxifene in the Prevention of Breast Cancer (STAR – NSABP). Contact Sopar Seributra, RN, Nurse Coordinator for STAR Study at 832-355-6777. PI – Philip A. Salem, MD, et al. Closed to accrual. Follow-up only.

Liver Cancer

SPORE Tumor Markers for Liver Cancer. PI – Omar Barakat, MD, 2007-2008.

Melanoma

SLEH 2408 ILX651-211-A2 – A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients with Inoperable Locally Advanced or Metastatic Melanoma. PI – Sewa S. Legha, MD Closed to accrual. Follow-up only.

SLEH 2594 Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination with Paclitaxel/ Carboplatin Chemotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma. PI – Sewa S. Legha, MD. Closed to accrual. Follow-up only.

Gynecologic Cancers

Genetic Determinants of Epithelial Invasiveness Relevant to Gynecologic Cancers. PI--Matthew L. Anderson, MD (H-14372)

MicroRNAs as Prognostic and Diagnostic Targets in Gynecologic Cancers. PI--Matthew L. Anderson, MD (H-22119)

Collaborative Gynecologic Tumor Bank. PI-- Matthew L. Anderson, MD (H-22124) Ongoing.

The Role of X Chromosome Inactivation in Ovarian Cancer Pathogenesis and Treatment. PI--Matthew L. Anderson, MD (H-23229)

A Phase 1 Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of Egen-001 in Combination with Carboplatin and Docetaxel in Women with Recurrent, Platinum-Sensitive, Epithelial Ovarian Cancer (Protocol Amendment 1.0 dated 22 May 2007 and Amendment to the Investigator’s Brochure dated March 21, 2007). PI-- Matthew L. Anderson, MD (H-20895)

SPORE Ovarian Tumor Tissue Sampling, PI--Matthew Anderson, MD, 2007-2008.

For the information on gynecologic cancer research projects, contact 713-798-7549.

Pancreas

A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVACTM –VF in Combination with GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients with Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen.

PI – William Fisher, MD (H-17145) 2005

A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer. PI – William Fisher, MD (H-17233) 2005

Pancreas Center Tissue Bank Specimen Collection. PI -- William Fisher, MD (H-16215) – Ongoing 2005, 2006, 2007 Ongoing.

A Phase III, Randomized Study of Gemcitabine (Fixed-dose Rate Infusion) and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma. PI--William Fisher, MD (H-15825). 2005

A Randomized, Phase II/III Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. PI--William Fisher, M.D. (H-17553) 2006

An Open Label Phase 2 Trial of Talabostat and Gemicitabine in Patients with Stage IV Adenocarcinoma of the Pancreas. PI--William Fisher, MD (H-19149) 2006

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely Resected Pancreatic Carcinoma. PI--William Fisher, MD (H-19176) 2006

A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naïve, Unresectable Pancreatic Adenocarcinoma. PI--William Fisher, MD (H-19234) 2006

A Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of Efficacy, Immunogenicity, and Safety of G1-4000: An Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant RAS Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo in Patients with Post-resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of RAS Mutations. (H-20777) PI --William Fisher, MD Open for enrollment. 2007

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of MORAB-009 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. (H-22673) PI--William Fisher, M.D. Open for enrollment. 2008.

Contact The Elkins Pancreas Center at Baylor College of Medicine at 1-877-PANC CTR.

Prostate

SPORE Tumor Marker Data: St. Luke’s urologists who are SPORE investigators participate in SPORE data collection and represent research excellence in prostate cancer clinical trials. St. Luke’s Cancer Registry contributes data collection. Brian J. Miles, MD, et al Ongoing.